Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oncology Pharma Inc (OP: ONPH ) 0.0002 +0.0001 (+100.00%) Streaming Delayed Price Updated: 1:27 PM EST, Jan 3, 2025 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 8,760 Open 0.0001 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0001 Today's Range 0.0001 - 0.0002 52wk Range 0.0001 - 0.1789 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News World Awaits Bankman-Fried Sentence, Drug Stock Pump-And-Dump, Penny Stock Fraud: Financial Crimes Weekly March 23, 2024 Prosecutors push for harshest punishment for Sam Bankman-Fried, convicted on fraud charges in FTX collapse. Defense seeks leniency. Via Benzinga Topics Fraud Lawsuit Exposures Criminal Legal Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System July 12, 2022 SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the... From Oncology Pharma Inc. Via AccessWire Performance YTD +100.00% +100.00% 1 Month +100.00% +100.00% 3 Month N/A N/A 6 Month +100.00% +100.00% 1 Year +100.00% +100.00% More News Read More Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System June 29, 2022 From Oncology Pharma Inc. Via AccessWire Exposures Product Safety Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development June 08, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development May 09, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer April 13, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Reports on Progress with Ribera Solutions March 02, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Releases Further Feasibility Studies, Data and Capacities February 23, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Expands on Feasibility Studies and Data February 17, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine February 14, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Gives Update on Technology, Formulation and Data Creation February 08, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma's New Year Update January 10, 2022 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Meeting Towards Future Developments December 17, 2021 From Oncology Pharma Inc. Via AccessWire Oncology Pharma Year End Review and Outlook December 09, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Oncology Pharma Research and Vision November 30, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate November 08, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress October 27, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing October 15, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures Intellectual Property Legal Regulatory Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement October 12, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product September 13, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives August 23, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. August 19, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP July 20, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase June 30, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties June 15, 2021 From Oncology Pharma Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
